Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

46461

Supelco

Metronidazol

VETRANAL®, analytical standard

Synonym(e):

2-Methyl-5-nitroimidazol-1-ethanol

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C6H9N3O3
CAS-Nummer:
443-48-1
Molekulargewicht:
171.15
Beilstein:
611683
EG-Nummer:
207-136-1
MDL-Nummer:
MFCD00009750
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329757194
NACRES:
NA.24

Qualität

analytical standard

Qualitätsniveau

200

Produktlinie

VETRANAL®

Haltbarkeit

limited shelf life, expiry date on the label

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

mp (Schmelzpunkt)

159-161 °C (lit.)

Wirkungsspektrum von Antibiotika

Gram-negative bacteria
parasites

Anwendung(en)

clinical testing

Format

neat

Wirkungsweise

DNA synthesis | interferes

Lagertemp.

2-8°C

SMILES String

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

InChIKey

VAOCPAMSLUNLGC-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Chemical structure: imidazole

Anwendung

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Empfohlene Produkte

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Rechtliche Hinweise

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Piktogramme

Health hazard
GHS08

Signalwort

Danger

Gefahreneinstufungen

Carc. 1B - Muta. 1B - STOT RE 2

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
BCCJ4839
BCCG8315
BCCB0355
BCBX3839
BCBW4436

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

Ronidazol-d3 VETRANAL®, analytical standard

Supelco

34217

Ronidazol-d3

Ronidazol analytical standard

Supelco

R7635

Ronidazol

Mebendazol analytical standard, ≥98% (HPLC)

Supelco

M2523

Mebendazol

Metronidazol Unreinheit A European Pharmacopoeia (EP) Reference Standard

Y0000087

Metronidazol Unreinheit A

Trimethoprim VETRANAL®, analytical standard

Supelco

46984

Trimethoprim

vibrant-m

M1851000

Metronidazolbenzoat

Dicloxacillin Natriumsalz Hydrat VETRANAL®, analytical standard

Supelco

46182

Dicloxacillin Natriumsalz Hydrat

Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks
Amber Howerton et al.
The Journal of infectious diseases, 207(10), 1498-1504 (2013-02-20)
Clostridium difficile infection (CDI) is a leading cause of antibiotic-associated diarrhea. The infective form of C. difficile is the spore, but the vegetative bacterium causes the disease. Because C. difficile spore germination is required for symptomatic infection, antigermination approaches could
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.